Calcitonin treatment for neurogenic claudication

Area of Science:

• Neurology
• Pharmacology

Background:

• Neurogenic claudication is a condition causing leg pain during walking due to spinal stenosis.
• Current treatments for neurogenic claudication have limitations.

Observation:

• Forty-one patients with suspected neurogenic claudication received Calcitonin for four weeks.
• Eleven patients showed significant improvement in walking distance.
• A subset of patients participated in a double-blind cross-over trial with positive outcomes.

Findings:

• Calcitonin demonstrated effectiveness in alleviating neurogenic claudication symptoms for a portion of the patient group.
• Five patients tolerated the drug for over a year without adverse effects.
• Two patients remained relapse-free after drug discontinuation.

Implications:

• Calcitonin may be a viable therapeutic option for select neurogenic claudication patients.
• Predictive factors for positive response include bilateral leg symptoms, limited walking distance, abnormal myelogram, and specific demographic/occupational profiles.
• The mechanism may involve an arterial shunt, redirecting blood flow to the cauda equina.